LY2886721

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

LY2886721 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Biologische Aktivität

  ly2886721 is an oral and furothiazine-based inhibitor of β site-amyloid protein cleaving enzyme (bace) with ic50 of 20.3nm. this product has the potency for the treatment of alzheimer's disease.bace, also known as beta-secretase 1, is an aspartic-acid protease that plays important role in the formation of myelin sheaths in peripheral nerve cells.in pdapp mice, oral administration of ly2886721 resulted in a reduction in brain aβ, c99 and sappβ in a dose-dependent pattern 2. aβ levels in the brain were decreased by 20% -65% as compared with the vehicle-treated groups 3 hours after treatment of ly2886721 at a dosage of 3-30 mg/kg per mice. in addition, ly2886721 significantly lowers plasma and csf aβs in the mad study 1.

• in vitro

  treatment of ly2886721 leads to the inhibition of aβ in hek293swe with ic50 of 18.7nm and pdapp neuronal culture with ic50 10.7 nm1. ly2886721 decreases csf sappβ and increases csf sappα in a dose- dependent manner 2.

• target

  BACE

• Einzelnachweise

  1. vassar r. bace1 inhibitor drugs in

LY2886721 Upstream-Materialien And Downstream Produkte

LY2886721 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(122)Suppliers

1262036-50-9, LY2886721 Verwandte Suche: